ALVR - Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against AlloVir Inc. (ALVR) | Benzinga

SAN DIEGO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired AlloVir, Inc. (NASDAQ:ALVR) securities between March 11, 2022 and December 21, 2023. AlloVir, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell ("VST") therapies to prevent and treat devastating viral-associated diseases.

For more information, submit a form, email Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What is this Case About: AlloVir, Inc. (ALVR) Allegedly Misled Investors Regarding Efficacy of its posoleucel Phase 3 Studies

According to the complaint, In March 2022, AlloVir initiated global phase 3 registrational studies of its lead product posoleucel for the prevention of life-threatening viral infections from viruses in high-risk, allogeneic hematopoietic cell transplant patients (the "posoleucel Phase 3 Studies").

Plaintiff alleges that during the class period, defendants failed to ...

ALVR)>Full story available on Benzinga.com